Skip to main content
. 2015 Jun 3;10(6):e0125837. doi: 10.1371/journal.pone.0125837

Fig 1.

Fig 1

Fig 1A: Prevalence of transmitted drug resistance mutations by study period and drug family according to the 2009 WHO list. Fig 1B: Prevalence of non-B HIV-1 subtypes and immigrants by study period. Footnote figure: NRTI indicates nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.